The value of primary site radiotherapy in stage Ⅳ high-risk neuroblastoma
10.3760/cma.j.issn.1004-4221.2012.01.005
- VernacularTitle:Ⅳ期高危神经母细胞瘤原发病变部位局部放疗的价值
- Author:
Juan WAGN
;
Zijun ZHEN
;
Juncheng LIU
;
Zhuowei LIU
;
Jia ZHU
;
Yue CAI
;
Jiayu LING
;
Yan CHEN
;
Ruiqing CAI
;
Xiaofei SUN
;
Yuanhong GAO
- Publication Type:Journal Article
- Keywords:
Nerve neoplasms/chemotherpy;
Nerve neoplasms/surgery;
Radiotherapy,postoperation;
Prognosis
- From:
Chinese Journal of Radiation Oncology
2012;21(1):13-15
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo investigated the effect of post-operative primary site radiotherapy on stage Ⅳ neuroblastoma.Methods From Jan 2003 to Dem 2010,47 newly diagnosed stage Ⅳ neuroblastoma treated in Sun Yet-sen university cancer center.The treatment protocol for these patients were induction chemotherapy 4- 12 cycles,followed by surgery if possible,then 4-6 cycles consolidation chemotherapy and/or primary site radiotherapy and maintenance immunotherapy.The median age was 4 years old,the median induction chemotherapy cycles was 5.37 patients received resection of the primary tumor (total resection and nearly gross resection).24 out of 37 received primary site radiotherapy.ResultsThe followup rate was 89％.34 cases were followed up more than 36 months.For patients with or without postoperative primary site radiotherapy,the local recurrence rate were 13％ ( 3/24 ) and 54％ ( 7/13 ),respectively ( P =0.016),the 3-year local control rate were 84％ and 47％,respectively ( χ2 =7.95,P =0.005 ).The 3-year overall survival rate were 56％ and 28％,respectively ( χ2 =5.44,P =0.020 ). There was no severe radiation side effect. Conclusions This study indicated that postoperative primary site after induction chemotherapy and surgery could reduce the local recurrence rate and possibly improve the overall survival rate of stage Ⅳ neuroblastoma.
